| Id: | acc3015 |
| Group: | 1sens_supp |
| Protein: | STAT3 |
| Gene Symbol: | Stat3 |
| Protein Id: | P42227 |
| Protein Name: | STAT3_MOUSE |
| PTM: | phosphorylation |
| Site: | Tyr705 |
| Site Sequence: | EADPGSAAPYLKTKFICVTPT |
| Disease Category: | Cardiovascular and circulatory system diseases |
| Disease: | Myocardial Infarction |
| Disease Subtype: | diabetes mellitus |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | rapamycin(RAPA) |
| Drug Info: | Rapamycin (RAPA) is a well - known immunosuppressant and autophagy inducer that has various applications in medical research and treatment. |
| Effect: | modulate |
| Effect Info: | "RAPA treatment significantly reduced the myocardial infarct size, myocardial cell necrosis and apoptosis in diabetic and wild - type mice, and simultaneously increased STAT3 phosphorylation and miRNA - 17/20a expression in diabetic hearts." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 31738412 |
| Sentence Index: | 31738412_15_supp |
| Sentence: | "RAPA-induced cardioprotection against I/R injury as well as the induction of miR-17/20a and AKT phosphorylation were abolished in cardiac-specific STAT3-deficient diabetic mice, without alteration of S6 phosphorylation. The infarct-limiting effect of RAPA was obliterated in cardiac-specific miRNA-17-92-deficient diabetic mice. The post-I/R restoration of phosphorylation of STAT3 and AKT with RAPA were also abolished in miRNA-17-92-deficient diabetic mice." |
Sequence & Structure:
MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMDLTSECATSPM
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 705 | U | Neurofibromatosis | Phosphorylation | 23318430 |
| Y | 705 | U | Squamous cell carcinoma | Phosphorylation | 19934324 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
